Jefferies Financial Group Comments on Immuneering Co.’s Q3 2022 Earnings (NASDAQ: IMRX)

Immuneering Co. (NASDAQ: IMRX – Get Rating) – Equities research analysts at Jefferies Financial Group lifted their Q3 2022 earnings per share (EPS) estimates for shares of Immuneering in a report issued on Tuesday, May 10th. Jefferies Financial Group analyst M. Yee now anticipates that the company will post earnings of ($ 0.52) per share for the quarter, up from their previous estimate of ($ 0.57). Jefferies Financial Group also issued estimates for Immuneering’s Q4 2022 earnings at ($ 0.54) EPS, FY2022 earnings at ($ 2.07) EPS, Q1 2023 earnings at ($ 0.56) EPS, Q2 2023 earnings at ($ 0.60) EPS, Q3 2023 earnings at ($ 0.64) EPS, Q4 2023 earnings at ($ 0.57) EPS and FY2023 earnings at ($ 2.36) EPS.

Other analysts have also issued reports about the company. Oppenheimer started coverage on Immuneering in a research report on Thursday, March 31st. They issued an “outperform” rating and a $ 25.00 price objective for the company. Zacks Investment Research upgraded Immuneering from a “hold” rating to a “buy” rating and set a $ 4.75 price objective on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Immuneering presently has an average rating of “Buy” and a consensus target price of $ 29.13.

Shares of NASDAQ IMRX opened at $ 5.05 on Friday. Immuneering has a 52-week low of $ 4.11 and a 52-week high of $ 33.99. The business has a fifty day moving average of $ 6.44 and a two-hundred day moving average of $ 13.79. Immuneering (NASDAQ: IMRX – Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($ 0.42) earnings per share for the quarter, missing the consensus estimate of ($ 0.39) by ($ 0.03). The business had revenue of $ 0.19 million during the quarter, compared to the consensus estimate of $ 0.60 million. Immuneering had a negative net margin of 21.73% and a negative return on equity of 43.21%.

A number of large investors have recently made changes to their positions in the business. UBS Group AG bought a new position in shares of Immuneering in the third quarter valued at approximately $ 30,000. Citigroup Inc. purchased a new position in shares of Immuneering in the third quarter valued at $ 33,000. New York State Common Retirement Fund purchased a new position in shares of Immuneering in the third quarter valued at $ 45,000. Metropolitan Life Insurance Co NY purchased a new position in Immuneering during the third quarter worth about $ 75,000. Finally, JPMorgan Chase & Co. grew its position in Immuneering by 119.5% during the first quarter. JPMorgan Chase & Co. now owns 11,969 shares of the company’s stock worth $ 78,000 after buying an additional 6,515 shares in the last quarter. Institutional investors and hedge funds own 47.41% of the company’s stock.

In other news, Director Ann E. Berman bought 6,000 shares of the company’s stock in a transaction on Tuesday, March 15th. The stock was purchased at an average cost of $ 6.40 per share, for a total transaction of $ 38,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired 10,900 shares of company stock valued at $ 73,621 over the last quarter.

Immuneering Company Profile (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and / or RAF; and IMM-6-415 to treat solid tumors.

Further Reading

Earnings History and Estimates for Immuneering (NASDAQ: IMRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Immuneering right now?

Before you consider Immuneering, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on … and Immuneering wasn’t on the list.

While Immuneering currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker